Landos Biopharma Inc

Landos Biopharma — Investor Presentation (February 2023)

21 slides from Landos Biopharma's investor presentation, Feb 28, 2023

  1. Slide 1: Corporate Overview

    Slide 1: Corporate Overview

    Corporate Overview February 28, 2023 Clinical stage biopharmaceutical company focused on the development of first-in-class therapeutics for patients with autoimmune disease. Exhibit 99.3

  2. Slide 2: Forward-looking statements

    Slide 2: Forward-looking statements

    This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our strategy, future operations, prospects, plans and objectives of manage

  3. Slide 3: Landos' Path Forward

    Slide 3: Landos' Path Forward

    SINGULAR FOCUS on advancing clinical development of NX-13 in Ulcerative Colitis (UC) NX-13 is a potential GAMECHANGER, with a novel mechanism of action (MOA), impressive safety profile, once-daily dosing with promising and early signals of clinical improvement (as soon as 2 weeks in patients’ sympto

  4. Slide 4: Landos' Novel Immunology Portfolio

    Slide 4: Landos' Novel Immunology Portfolio

    Landos’ Novel Immunology Portfolio 2 8 4 Novel target (NLRX1 and PLXDC2) libraries of immunometabolic modulation pathways Potentially first-in-class, once-daily, oral therapeutics upstream of multiple canonical inflammatory/ regulatory pathways Indications in the immunology space targeted by broadly

  5. Slide 5: Broad Portfolio of Clinical & Pre-clinical Programs

    Slide 5: Broad Portfolio of Clinical & Pre-clinical Programs

    Broad Portfolio of Clinical & Pre-clinical Programs NX-13 (entering Phase 2 for UC): Novel, oral, gut-selective NLRX1 agonist in development for the treatment of Ulcerative Colitis and Crohn’s Disease as a once-daily treatment LABP-66 (pre-clinical): Novel, oral, once-daily, product candidate target

  6. Slide 6: Landos Strategy: Advancing NX-13 in UC is the Company's Focus

    Slide 6: Landos Strategy: Advancing NX-13 in UC is the Company's Focus

    6 Landos Strategy: Advancing NX-13 in UC is the Company’s Focus *NX-13 Phase 1b study was not designed or powered for exploratory clinical endpoints therefore results are hypothesis-generating only NX-13 is the Top Priority Impressive & Emerging Data Foundation Supports Dual Focus Clear Path Forward

  7. Slide 7: UC is an Attractive & Growing Market Opportunity

    Slide 7: UC is an Attractive & Growing Market Opportunity

    Global Sales ($M): 2020 and 2030 UC is an Attractive & Growing Market Opportunity Source: Clarivate 2020 2030 Global UC Diagnosed Patients: 2020 – 2030 Source: Clarivate Source: 2022 Decision Resource Group (Clarivate) UC Disease Landscape and Forecast including 2030 projected data Global UC Sales (

  8. Slide 8: NX-13 Poised for Broad Utilization in both Early & Late-Stage Disease

    Slide 8: NX-13 Poised for Broad Utilization in both Early & Late-Stage Disease

    Aminosalicylates (5-ASA) Mesalamine, Sulfasalazine Immunosuppressants Methotrexate, thiopurines Corticosteroids Budesonide, Prednisone Alpha-4-beta-7 integrin Entyvio TNF-alpha inhibitors Humira, Remicade, Cimzia IL-12/IL-23 Oral Approaches S1P1, JAK, miRNA Pathways MILD MODERATE SEVERE NX-13 Poised

  9. Slide 9: NLRX1 Library

    Slide 9: NLRX1 Library

    NLRX1 Library

  10. Slide 10: NLRX1 Activation Reduces Inflammatory Cytokines, Cells & Signaling Pathways

    Slide 10: NLRX1 Activation Reduces Inflammatory Cytokines, Cells & Signaling Pathways

    NLRX1 Activation Reduces Inflammatory Cytokines, Cells & Signaling Pathways

  11. Slide 11: NX-13 Profile

    Slide 11: NX-13 Profile

    NX-13 Profile Mechanism of Action Drug Profile Recent & Upcoming Milestones Targets NLRX1 pathway, a mitochondrial-associated regulatory NOD-like receptor Bimodal MOA aims to decrease reactive oxygen species and oxidative stress, while decreasing pro-inflammatory signals No on-target toxicities asso

  12. Slide 12: Phase 1b Study Design of NX-13 in Active UC

    Slide 12: Phase 1b Study Design of NX-13 in Active UC

    Phase 1b Study Design of NX-13 in Active UC IR = Immediate Release; MR = Modified Release Note: Study was not designed or powered for exploratory clinical endpoints therefore results are hypothesis-generating only Group 1: NX-13 250mg IR n=12 Group 4: Placebo n = 4 Week 2 Week 4 EOT Group 3: NX-13 5

  13. Slide 13: Phase 1b Results: Reductions in Multiple Clinical Measures after 4 weeks

    Slide 13: Phase 1b Results: Reductions in Multiple Clinical Measures after 4 weeks

    Clinical Response Defined as CFB of at least -3, or -30% in Mayo Score Histologic Remission Geboes <3.1, no increased neutrophils in the LP Endoscopic Response MES CFB of at least -1 Phase 1b Results: NX-13 Treated Patients Experienced Reductions in Multiple Clinical Measures after 4 weeks IR= Immed

  14. Slide 14: Phase 1b Results: Symptomatic Remission in Rectal Bleeding & Stool Frequency

    Slide 14: Phase 1b Results: Symptomatic Remission in Rectal Bleeding & Stool Frequency

    Patients in the 250mg group had the greatest reduction of Rectal Bleeding and Stool Frequency at 2 weeks, with further reduction at 4 weeks Majority of patients saw complete resolution of BOTH rectal bleeding and stool frequency after 4 weeks of treatment with NX-13 250mg, once daily Phase 1b Result

  15. Slide 15: Phase 1b Results: NX-13 Well-Tolerated with Promising Signs of Clinical Improvement

    Slide 15: Phase 1b Results: NX-13 Well-Tolerated with Promising Signs of Clinical Improvement

    Generally well tolerated, consistent with non-clinical, Phase 1a data No Serious Adverse Events 3 unrelated Adverse Events (AEs) of note 4 weeks of low dose, immediate release, once daily treatment induced: Clinical response in 8/11 patients Clinical remission in 3/11 patients Endoscopic and Histolo

  16. Slide 16: What's Next: Study Design for NX-13 Phase 2 Proof of Concept Trial

    Slide 16: What's Next: Study Design for NX-13 Phase 2 Proof of Concept Trial

    What’s Next: Study Design for NX-13 Phase 2 Proof of Concept Trial GOAL | Evaluate the safety, efficacy and pharmacokinetics of NX-13 in moderate to severe UC patients. TIMING | On-track to initiate Phase 2 trial in Q2 2023; Expecting to report topline data by Q4 2024 ADDITIONAL PHASE 2 LEARNINGS |

  17. Slide 17: Preclinical Programs in the NLRX1 Agonist Library

    Slide 17: Preclinical Programs in the NLRX1 Agonist Library

    Preclinical Programs in the NLRX1 Agonist Library 17 LABP-73 for Respiratory Inflammation LABP-66 for CNS Inflammation Key Indications Asthma, COPD MS, AlzD Administration Oral, once-daily Oral, once-daily Development Stage Preclinical Development Preclinical Development Additional Information MOA s

  18. Slide 18: PLXDC2 Library

    Slide 18: PLXDC2 Library

    PLXDC2 Library B1OPHARMA

  19. Slide 19: Activation of PLXDC2 Suppresses Inflammation & Angiogenesis

    Slide 19: Activation of PLXDC2 Suppresses Inflammation & Angiogenesis

    Activation of PLXDC2 in Immune & Non-Immune Cells Suppresses Inflammation & Angiogenesis

  20. Slide 20: Preclinical Programs in the PLXDC2 Agonist Library

    Slide 20: Preclinical Programs in the PLXDC2 Agonist Library

    Preclinical Programs in the PLXDC2 Agonist Library 20 LABP-69 Key Indications Rheumatoid Arthritis (“RA”), Diabetic Nephropathy Administration Oral, once-daily Development Stage Preclinical Development Additional Information MOA: Designed to decrease reactive oxygen species, oxidative stress, pro-in

  21. Slide 21: Landos Biopharma

    Slide 21: Landos Biopharma

    LANDOS BIlOPHARMA

Source: SEC EDGAR · 8-K filed Feb 28, 2023

More decks from Landos Biopharma Inc